Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07336056 · ClinicalTrials.gov registry record · Phase 4
Nerivio Efficacy Under High-Frequency Use
A Phase 4 study of Migraine, sponsored by Theranica.
- Active
- Registry status
- Phase 4
- Development phase
- 2,000
- Enrollment target
- 1
- Study location
NCT07336056: Active Phase 4 study of Migraine, sponsored by Theranica.
NCT07336056 is a Phase 4 study of Migraine that is active but no longer recruiting, run by Theranica. The registered enrollment target is 2,000 participants, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (490% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07336056, a Phase 4 study of Migraine, is active but no longer recruiting, sponsored by Theranica.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine. This study assessed the safety and tolerability of REN when used at frequencies exceeding the labeled indication.
Primary Outcome
Rate of serious adverse events, adverse events and device-related adverse events
Conditions Studied
Interventions
- DEVICE Nerivio (REN device)
Study Locations (1)
New Jersey
- Theranica USA Inc - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 4 |
What the registry record for NCT07336056 still lists
NCT07336056 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (490% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Nerivio (REN device) is the first listed.
NCT07336056 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07336056 about?
NCT07336056 is a clinical study titled "Nerivio Efficacy Under High-Frequency Use". This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine. This study assessed the safety and tolerability of REN when used at frequencies exceeding the labeled indication.
What is the current status of trial NCT07336056?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,000 participants. The study started on 2026-01-08. Estimated completion is 2026-01-30.
What conditions does trial NCT07336056 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT07336056?
The interventions under investigation include: Nerivio (REN device) (DEVICE).
Who is sponsoring clinical trial NCT07336056?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07336056 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07336056's enrollment target sits among peer trials
2,000 2nd of 102 the highest of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI